Johnson & Johnson JNJ

$282.11 +5.89 (2.13%)

Valuation

Market cap
664,947,200,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
25.57
P/E (forward)
24.50
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
6,904,400
Avg volume
7,236,090
Day's range
$276.20 – $282.73
Shares out
2,407,310,000
Stochastic %K
97%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

nwgy Nov 10, 2:36 PM
$ISRG— $JNJ essentially admitted they are unable to do robotic staplers. They are touting a hybrid approach for stapling. Intuitive’s monopoly is here to stay.
0 replies
DoubleUpwithChuck Nov 10, 2:28 PM
$ZPTA tag pharma. Tell them on Twitter $LLY $JNJ $BAYRY Some of them have a ton of cash for quantum drug discovery projects
0 replies
HydrogenH2 Nov 10, 1:22 PM
$JNJ Take some profits before that baby powder litigations take some $$$
0 replies
Rayvio_News_Filter Nov 10, 1:06 PM
$JNJ 🏥 Johnson & Johnson announced CAPLYTA (lumateperone) met primary and key secondary endpoints in a second pivotal Phase 3 study for bipolar I mania, with improvement versus placebo as early as Day 3 through Week 3; two positive studies support a planned U.S. FDA submission. Actionable market event
0 replies
jrodpikap Nov 10, 1:05 PM
$SLS Love the way $JNJ has been climbing the past month, give them more Market Cap for the impending Buy Out of $SLS
1 replies
HydrogenH2 Nov 10, 11:06 AM
$JNJ When Cramer says "Buy" @ 52 week high... Take some profits folks !!!
0 replies
trenddetector Nov 9, 11:10 PM
$JNJ YourCancerPath.com now covers Johnson & Johnson's Rybrevant and Lazcluze for EGFR lung cancer, Inlexzo for bladder cancer, and Tecvayli with Darzalex Faspro for multiple myeloma. It's a free patient guide, written in plain language. https://www.yourcancerpath.com/multiple-myeloma/ Not investment advice.
1 replies
RallyRocket Nov 9, 10:53 PM 0 replies